Aller au contenu principal
Accès ouvert déclaré 2026 article

Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024

0Citations signalées — pas une note de qualité
11Institutions déclarées
1Pays d’affiliation déclarés

Résumé fourni par la source

BACKGROUND: Implementation of long-acting cabotegravir/rilpivirine (LA-CAB/RPV) has been challenging and may limit its uptake. We describe the number of people with HIV (PWH) prescribed LA-CAB/RPV at 9 US academic HIV clinics in the Center for AIDS Research Network of Integrated Clinical Systems and clinic-level variation in LA-CAB/RPV prescriptions. METHODS: Using a sequential explanatory mixed methods design, we analyzed clinical cohort data of PWH prescribed LA-CAB/RPV, then conducted key informant surveys to ascertain each clinic's Exploration-Preparation-Implementation-Sustainment phase in conjunction with implementation determinants mapped to the Consolidated Framework for Implementation Research. We stratified the cohort analysis by phase. RESULTS: Between 21-Jan-2021 and 30-Sep-2024, 1,451 (6%) of 22,379 PWH in care were prescribed LA-CAB/RPV. Among those prescribed, 15% had baseline viral load ≥200 copies/mL (200/1,451). Two sustainment-phase clinics that experienced fewer insurance-related barriers, planned prior to LA-CAB/RPV availability, had a pharmacy team coordinating LA-CAB/RPV services, and customized the electronic health record (EHR) system to track insurance approvals and/or injection appointments prescribed LA-CAB/RPV to 16% (924/5,638) of PWH in care. Four sustainment-phase clinics that had a mix of payor coverage and insurance plans, and adequate staffing prescribed to 3% (213/8,154). Three implementation-phase clinics with difficulty procuring LA-CAB/RPV due to restrictive insurance coverage and/or hospital policy and staffing challenges prescribed to 4% (314/8,587). CONCLUSIONS: Barriers related to insurance coverage and drug procurement impacted the number of PWH prescribed LA-CAB/RPV as did processes to plan for, and adapt to, these barriers. Scale-up efforts should consider team coordination and EHR-facilitated tracking to support the growing number of PWH on LA-CAB/RPV.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024
Date Crossref
31/08/2026
Éditeur
Ovid Technologies (Wolters Kluwer Health)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

HIV/AIDS Research and InterventionsRespiratory viral infections researchHealth Policy Implementation Science

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.